Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis.

@article{Camelo2005TranscriptionalTW,
  title={Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis.},
  author={Sandra I Camelo and Antonio H. Iglesias and Daehee Hwang and Brice Due and Hoon Ryu and Karen Vail Smith and Steven G Gray and Jaime Imitola and German Duran and Basel T Assaf and Brett C Langley and Samia J Khoury and George Stephanopoulos and Umberto De Girolami and Rajiv R Ratan and Robert Ferrante and Fernando Dangond},
  journal={Journal of neuroimmunology},
  year={2005},
  volume={164 1-2},
  pages={10-21}
}
We demonstrate that the histone deacetylase (HDAC) inhibitor drug trichostatin A (TSA) reduces spinal cord inflammation, demyelination, neuronal and axonal loss and ameliorates disability in the relapsing phase of experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis (MS). TSA up-regulates antioxidant, anti-excitotoxicity and pro-neuronal growth and differentiation mRNAs. TSA also inhibits caspase activation and down-regulates gene targets of the pro-apoptotic E2F… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
108 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 108 extracted citations

Similar Papers

Loading similar papers…